Stoke与Biogen公布zorevunersen治疗Dravet综合征4年开放标签延伸数据：持续减少发作并改善认知行为

【原文标题】Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)